How Machine Perfusion is Revolutionizing Liver Transplants by Reversing Organ Aging

The Limits of Traditional Organ Preservation

Once an organ is removed from a donor, it begins to degrade rapidly. The standard practice involves flushing the organ with a cold preservative solution and storing it on ice. While this method slows metabolic processes, it does not stop cellular damage, limiting the time surgeons have to transplant the organ—typically just a few hours.

This time constraint restricts the pool of usable organs and increases the risk of organ failure post-transplant. Organs from older donors or those with health issues are often discarded due to concerns about their viability, contributing to shortages and long waiting lists for recipients.

Machine Perfusion: Mimicking Life Outside the Body

Machine perfusion technology pumps donated livers with oxygenated blood or nutrient-rich solutions at controlled temperatures, usually around 34 degrees Celsius. This method simulates the organ’s natural environment, allowing it to maintain metabolic activity and repair some damage.

Hospitals increasingly use this technique, especially for organs that are considered marginal or from donors with circulatory death, where blood flow stops before organ retrieval. Perfusion times typically range from six to twelve hours, providing a longer window for assessment and potential intervention.

Besides preservation, machine perfusion enables transplant teams to evaluate organ function more accurately before implantation, potentially reducing the risk of transplant failure.

Scientific Breakthrough: Reversing Biological Age in Donated Livers

A recent study led by researchers at Brigham and Women’s Hospital and Mass General Brigham has demonstrated that machine-perfused livers exhibit a younger biological age compared to those stored on ice. Using epigenetic 'aging clocks'—tools that analyze chemical markers on DNA to estimate biological age—the team found that perfused livers had molecular signatures indicating rejuvenation.

In one experiment involving 37 samples from 19 donated livers, perfused organs showed lower biological age despite being chronologically older or having other risk factors. A larger follow-up study with 208 samples from 103 livers confirmed these findings using different aging clocks that measure gene activity and risk of death.

The researchers observed that pumping livers with oxygen and nutrients reversed biological aging by approximately 30% compared to cold storage. Although biological age increased after transplantation due to physiological stresses, perfused livers remained younger than their non-perfused counterparts.

Molecular Insights and Potential Therapeutic Advances

At the molecular level, perfused livers showed changes in pathways related to inflammation, tissue structure, and autophagy—the process by which cells remove and recycle damaged components. These changes suggest that machine perfusion not only preserves but actively repairs cellular damage, contributing to the observed rejuvenation.

The researchers aim to develop diagnostic tests based on biological age to better assess organ suitability for transplantation. They are also exploring drug treatments that might mimic or enhance the rejuvenating effects of perfusion, potentially offering a more cost-effective alternative.

Such innovations could significantly increase the number of viable organs, especially from older donors, and improve transplant success rates.

Economic and Practical Considerations in Organ Perfusion

Despite its benefits, machine perfusion is currently expensive. In Germany, the cost per organ is around €10,000, accounting for about a quarter of the transplant budget. In the United States, costs can reach $80,000 to $100,000 per organ. These expenses pose challenges for widespread adoption, especially in resource-constrained healthcare systems.

However, the potential to reduce organ discard rates and improve patient outcomes may offset these costs in the long term. For example, perfusion has enabled the use of livers from donors over 70 years old or those who experienced circulatory death—organs that were previously considered too risky.

As the technology matures and becomes more accessible, it could transform transplantation practices in Nigeria and other countries facing organ shortages.

Implications for Nigerian and Global Transplantation Markets

Nigeria, like many countries, struggles with limited organ donation and transplantation infrastructure. The introduction of machine perfusion technology could help maximize the utility of available organs, reduce waiting times, and improve transplant outcomes.

Moreover, understanding and applying biological aging metrics could lead to better organ matching and personalized treatment plans, enhancing patient care.

Globally, this research underscores the importance of integrating cutting-edge biotechnology with clinical practice to address the growing demand for organ transplants. It also highlights opportunities for local biotech firms and healthcare providers to innovate in organ preservation and transplantation services.

Future Directions and Challenges

Further research is needed to understand how machine perfusion affects organs from very elderly donors, such as those in their 70s and 80s, which are increasingly used in transplantation.

Developing affordable, scalable perfusion systems and complementary therapies will be crucial for broader adoption, particularly in low- and middle-income countries.

Regulatory and ethical considerations around organ ownership during the perfusion process and the implementation of new testing methods must also be addressed.

Nevertheless, the current findings mark a significant step toward improving organ transplantation outcomes and expanding the donor pool.

What this means

The advent of machine perfusion marks a transformative shift in organ transplantation, turning donated livers into biologically younger, more resilient organs. This breakthrough not only enhances the success rates of liver transplants but also opens doors to utilizing organs that were previously deemed unsuitable due to age or condition. While the technology's high cost remains a barrier, ongoing research into molecular mechanisms and adjunct therapies promises to make organ rejuvenation more affordable and widely available. For Nigeria and the global transplant community, embracing such innovations could alleviate organ shortages, improve patient outcomes, and reshape the future of transplantation medicine.